NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registra ...

Core Viewpoint - A class action securities lawsuit has been filed against DeFi Technologies, alleging securities fraud that affected investors between May 12, 2025, and November 14, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DeFi Technologies faced delays in executing its DeFi arbitrage strategy, which was a key revenue driver for the company [2]. - It is alleged that DeFi Technologies understated the competition from other digital asset treasury companies, impacting its ability to execute its DeFi arbitrage strategy [2]. - The complaint suggests that due to these issues, the company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025 [2]. - Defendants are accused of downplaying the negative impact of these issues on DeFi Technologies' business and financial results, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses in DeFi Technologies during the relevant timeframe have until January 30, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Perrigo Company plc ("Perrigo Company plc" or the "Company") (NYSE: PRGO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Perrigo Company plc investors who were adversely affected by alleged securities fraud between February 27, 2023 and November 4, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1 ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in James Hardie Industries plc. ("James Hardie Industries plc." or the "Company") (NYSE: JHX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of James Hardie Industries plc. investors who were adversely affected by alleged securities fraud between May 20, 2025 and August 18, 2025. Follow the link below to get more information and be contacted by a member of our team: htt ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2] - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2] - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [2] - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [2] - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2] Group 2: Next Steps for Investors - Investors who suffered losses in Baxter International, Inc. during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - A class action securities lawsuit has been filed against Stride, Inc. for alleged securities fraud affecting investors between October 22, 2024, and October 28, 2025 [1] Group 1: Allegations Against Stride - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" [2] - It is alleged that Stride cut staffing costs by assigning teachers caseloads beyond statutory limits [2] - The company is accused of ignoring compliance requirements, including background checks and licensure laws for employees, as well as federally mandated special education services [2] - Whistleblowers who documented financial directives from Stride's leadership were reportedly suppressed to maintain profit margins [2] - The company allegedly lost existing and potential enrollments due to these practices [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 12, 2026, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against Firefly Aerospace Inc. due to alleged securities fraud affecting investors who purchased shares during the company's IPO and subsequent period [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who acquired Firefly common stock during its IPO on August 7, 2025, and between August 7, 2025, and September 29, 2025 [2]. - The complaint alleges that Firefly overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program, which could have a material negative impact on the company [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until January 12, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Skye Bioscience, Inc. due to alleged securities fraud affecting investors between November 4, 2024, and October 3, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that the defendants made false statements regarding the effectiveness of the Company's lead product candidate, nimacimab, which was claimed to be less effective than represented [2]. - It is asserted that the clinical, regulatory, and commercial prospects of nimacimab were overstated, leading to materially false and misleading public statements by the defendants [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].